search
Back to results

Intravenous Lidocaine in Bariatric Surgery. (XYLOBAR)

Primary Purpose

Morbid Obesity, Bariatric Surgery Candidate

Status
Unknown status
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Lidocaine
isotonic saline
Sponsored by
University Hospital, Caen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Morbid Obesity focused on measuring bariatric surgery, rehabilitation, lidocaine

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • scheduled bariatric surgery

Exclusion Criteria:

  • any contra-indication for lidocaine administration
  • pregnancy
  • ASA class 4
  • psychiatric disorder
  • chronic opioid consumption

Sites / Locations

  • University Hospital of Caen

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Control

Lidocaine

Arm Description

intravenous isotonic saline administration : bolus of 0.075 ml/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (0.1 ml/kg/h, adjusted body weight) until the end of surgery decrease to 0.05 ml/kg (adjusted body weight) during 60 min in post anesthesia care unit. Speed of infusion were calculated to be equivalent to that of lidocaine speed of injection.

Intravenous Lidocaine (20mg/ml) : bolus of 1.5 mg/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (2.0 mg/kg/h, adjusted body weight) until the end of surgery decrease to 1.0 mg/kg (adjusted body weight) during 60 min in post anesthesia care unit.

Outcomes

Primary Outcome Measures

oxycodone consumption
total postoperative (until day 3) oxycodone consumption (mg)

Secondary Outcome Measures

lidocaine plasma concentration
lidocaine plasma concentration measured at the end of infusion
hospital discharge check list
recovery (in days) which enable discharge from hospital
postoperative pain
postoperative pain intensity (visual analogue scale)
nausea and vomiting
proportion of patients with and without postoperative nausea and vomiting
intestinal transit recovery
duration (in days) of postoperative intestinal palsy
hospital length of stay
hospital length of stay

Full Information

First Posted
May 31, 2017
Last Updated
July 12, 2017
Sponsor
University Hospital, Caen
search

1. Study Identification

Unique Protocol Identification Number
NCT03211455
Brief Title
Intravenous Lidocaine in Bariatric Surgery.
Acronym
XYLOBAR
Official Title
Effect of Continuous Intravenous Lidocaine on Early Rehabilitation in Bariatric Surgery. A Randomized Double Blind Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2017
Overall Recruitment Status
Unknown status
Study Start Date
August 1, 2017 (Anticipated)
Primary Completion Date
February 1, 2019 (Anticipated)
Study Completion Date
May 1, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Caen

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Although peroperative intravenous lidocaine has been shown to be useful in early recovery after colorectal surgery, its beneficial effect on the specific population of obese patients scheduled for bariatric surgery remained unknown. Investigators hypothesized that peroperative intravenous lidocaine could decrease postoperative opioid consumption and improve postoperative recovery
Detailed Description
This is a prospective, double-blind, placebo-controlled, monocentric study. We plan to recruit 180 obese adult patients scheduled for bariatric surgery in a the french university hospital of Caen. Exclusion: contra-indications for any aminoamide local anesthetic (allergy, severe hepatic disease) and for intravenous lidocaine (porphyria, atrioventricular conduction disturbances, uncontrolled seizure disease), long term opioid consumption, need for a post-operative follow-up in an intensive care unit, combined surgical procedure excepting cholecystectomy, pregnancy. Patients will be randomly allocated to receive either a saline placebo or lidocaine continuous infusions during surgery. Morphinic consumption will be assessed from the end of the procedure until the third day after surgery. Secondary criteria will concern post-operative recovery, pain and postoperative nausea and vomiting, other medical and surgical complications, and toxicity. Plasma lidocaine concentrations will be measured in patients who had received lidocaine in order to determine the safety and efficiency of our infusion protocol. Our analysis will be a superiority one, alpha risk is 5% and beta risk is 20%, in intention to treat, with no intermediate analysis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Morbid Obesity, Bariatric Surgery Candidate
Keywords
bariatric surgery, rehabilitation, lidocaine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
180 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
intravenous isotonic saline administration : bolus of 0.075 ml/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (0.1 ml/kg/h, adjusted body weight) until the end of surgery decrease to 0.05 ml/kg (adjusted body weight) during 60 min in post anesthesia care unit. Speed of infusion were calculated to be equivalent to that of lidocaine speed of injection.
Arm Title
Lidocaine
Arm Type
Experimental
Arm Description
Intravenous Lidocaine (20mg/ml) : bolus of 1.5 mg/kg (adjusted body weight) at induction of anesthesia followed by a continuous infusion (2.0 mg/kg/h, adjusted body weight) until the end of surgery decrease to 1.0 mg/kg (adjusted body weight) during 60 min in post anesthesia care unit.
Intervention Type
Drug
Intervention Name(s)
Lidocaine
Intervention Description
intravenous lidocaine versus placebo
Intervention Type
Drug
Intervention Name(s)
isotonic saline
Other Intervention Name(s)
saline
Intervention Description
intravenous isotonic saline
Primary Outcome Measure Information:
Title
oxycodone consumption
Description
total postoperative (until day 3) oxycodone consumption (mg)
Time Frame
three days following surgery
Secondary Outcome Measure Information:
Title
lidocaine plasma concentration
Description
lidocaine plasma concentration measured at the end of infusion
Time Frame
during post anesthesia care unit stay (1 day)
Title
hospital discharge check list
Description
recovery (in days) which enable discharge from hospital
Time Frame
three days following surgery
Title
postoperative pain
Description
postoperative pain intensity (visual analogue scale)
Time Frame
three days following surgery
Title
nausea and vomiting
Description
proportion of patients with and without postoperative nausea and vomiting
Time Frame
three days following surgery
Title
intestinal transit recovery
Description
duration (in days) of postoperative intestinal palsy
Time Frame
three days following surgery
Title
hospital length of stay
Description
hospital length of stay
Time Frame
through hospital discharge (an average of 1 week)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: scheduled bariatric surgery Exclusion Criteria: any contra-indication for lidocaine administration pregnancy ASA class 4 psychiatric disorder chronic opioid consumption
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
fabien chaillot
Phone
+33 2 31 06 57 81
Email
chaillot-f@chu-caen.fr
First Name & Middle Initial & Last Name or Official Title & Degree
fabien chaillot
Phone
+33 2 31 06 57 81
Facility Information:
Facility Name
University Hospital of Caen
City
Caen
ZIP/Postal Code
14033
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intravenous Lidocaine in Bariatric Surgery.

We'll reach out to this number within 24 hrs